HRP20230752T1 - Cjepivo protiv slinavke i šapa - Google Patents

Cjepivo protiv slinavke i šapa Download PDF

Info

Publication number
HRP20230752T1
HRP20230752T1 HRP20230752TT HRP20230752T HRP20230752T1 HR P20230752 T1 HRP20230752 T1 HR P20230752T1 HR P20230752T T HRP20230752T T HR P20230752TT HR P20230752 T HRP20230752 T HR P20230752T HR P20230752 T1 HRP20230752 T1 HR P20230752T1
Authority
HR
Croatia
Prior art keywords
preparation according
immunogenic preparation
strain
fmd
cruzeiro
Prior art date
Application number
HRP20230752TT
Other languages
English (en)
Inventor
Paul Joseph Dominowski
John Morgan Hardham
James Alan JACKSON
Cyril Gerard GAY
Luis Leandro RODRIGUEZ
Peter William KRUG
Aida Elizabeth Rieder
Original Assignee
Zoetis Services Llc
The United States Of America, As Represented By The Secretary Of Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc, The United States Of America, As Represented By The Secretary Of Agriculture filed Critical Zoetis Services Llc
Publication of HRP20230752T1 publication Critical patent/HRP20230752T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/135—Foot- and mouth-disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32111—Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (14)

1. Imunogeni pripravak koji sadrži antigensku komponentu i adjuvantnu komponentu, naznačen time što a) adjuvantna komponenta sadrži emulziju koja sadrži ulje, imunostimulacijski oligonukleotid koji sadrži CpG, te dietlaminoetildekstran (DEAE-dekstran); i b) antigenska komponenta sadrži 0,5-10 µg pripravka inaktiviranog soja Cruzeiro virusa FMD (slinavke i šapa) po dozi.
2. Imunogeni pripravak u skladu s patentnim zahtjevom 1, naznačen time što je imunostimulacijski oligonukleotid imunostimulacijski oligonukleotid klase P.
3. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što imunostimulacijski oligonukleotid sadrži najmanje 15 uzastopnih nukleotida iz SEQ ID NO: 8.
4. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je volumni postotak ulja 40% do 85% vol./vol. pripravka.
5. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačen time što je volumni postotak ulja 44-50% vol./vol. pripravka.
6. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što dodatno sadrži jedan ili više emulgatora.
7. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što adjuvantna komponenta sadrži SEQ ID NO: 8.
8. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što je DEAE Dextran prisutan u količini od 6-200 mg po dozi i/ili što je imunostimulacijski oligonukleotid prisutan u količini od 6-200 µg po dozi.
9. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je navedeni soj Cruzeiro virusa FMD genetički modificiran i sadrži deleciju područja koje kodira vodeći slijed (LL) i dodatno može sadržavati kapsidni protein iz heterolognog soja.
10. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što navedeni soj Cruzeiro virusa FMD sadrži negativne antigenske biljege, unesene u jedan ili oba od virusnih nestrukturnih proteina 3Dpol i 3B.
11. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 9 ili 10, naznačen time što navedeni soj Cruzeiro virusa FMD sadrži heterologni kapsidni protein.
12. Imunogeni pripravak u skladu s patentnim zahtjevom 11, naznačen time što se soj koji nije Cruzeiro bira između Asia1, Turkey06, O1Campos, C3Indaial, te A2001-Argentina.
13. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-12, naznačen time što antigenska komponenta sadrži 0,5-6 µg virusa FMD po dozi.
14. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 1-13, naznačen time što je namijenjen upotrebi u postupku sprječavanja FMD kod životinje kojoj je to potrebno, koji uključuje primjenu imunogenog pripravka na navedenoj životinji.
HRP20230752TT 2015-01-16 2016-01-15 Cjepivo protiv slinavke i šapa HRP20230752T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562104314P 2015-01-16 2015-01-16
EP16704959.2A EP3244920B1 (en) 2015-01-16 2016-01-15 Foot-and-mouth disease vaccine
PCT/US2016/013587 WO2016115456A1 (en) 2015-01-16 2016-01-15 Foot-and-mouth disease vaccine

Publications (1)

Publication Number Publication Date
HRP20230752T1 true HRP20230752T1 (hr) 2023-10-27

Family

ID=55361946

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230752TT HRP20230752T1 (hr) 2015-01-16 2016-01-15 Cjepivo protiv slinavke i šapa

Country Status (27)

Country Link
US (4) US10478487B2 (hr)
EP (2) EP3244920B1 (hr)
JP (4) JP7113620B2 (hr)
KR (3) KR20170097116A (hr)
CN (3) CN115317600A (hr)
AR (1) AR103427A1 (hr)
AU (2) AU2016206525A1 (hr)
BR (1) BR112017015288A2 (hr)
CA (1) CA2973828C (hr)
CO (1) CO2017007057A2 (hr)
DK (1) DK3244920T5 (hr)
ES (1) ES2950822T3 (hr)
FI (1) FI3244920T3 (hr)
HK (1) HK1246659A1 (hr)
HR (1) HRP20230752T1 (hr)
HU (1) HUE063288T2 (hr)
IL (1) IL253137B2 (hr)
LT (1) LT3244920T (hr)
MX (2) MX2017009306A (hr)
PH (1) PH12017501257A1 (hr)
PL (1) PL3244920T3 (hr)
PT (1) PT3244920T (hr)
RU (1) RU2698305C2 (hr)
SG (1) SG11201705737RA (hr)
SI (1) SI3244920T1 (hr)
WO (1) WO2016115456A1 (hr)
ZA (1) ZA201704596B (hr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3244920T1 (sl) * 2015-01-16 2023-09-29 The United States of America, represented by The Secretary of Agriculture, United States Department of Agriculture Cepivo proti slinavki in parkljevki
CN106474466B (zh) * 2016-12-07 2018-04-13 申联生物医药（上海）股份有限公司 一种口蹄疫疫苗的制备方法
AU2018390817A1 (en) * 2017-12-20 2020-06-25 Zoetis Services Llc Vaccines against Hendra and Nipah virus infection
KR102285977B1 (ko) 2019-03-15 2021-08-05 대한민국 오일 에멀젼과 병용 투여 가능한 면역증강용 보조물질 및 이를 포함하는 구제역 백신 조성물
CN112516325B (zh) * 2019-09-18 2023-12-08 洛阳赛威生物科技有限公司 一种稳定的口蹄疫疫苗组合物及其应用
WO2021242879A1 (en) * 2020-05-27 2021-12-02 The United States Of America, As Represented By The Secretary Of Agriculture Live attenuated strains of foot and mouth disease modified by deoptimization and uses thereof
WO2024194885A1 (en) * 2023-03-21 2024-09-26 Indian Council Of Agricultural Research Vaccine compositions and methods for control of foot and mouth disease

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR228580A1 (es) 1980-11-25 1983-03-30 Torre Jose Leonardo Procedimiento para inactivar el virus de la fiebre aftosa
US4732971A (en) 1985-06-03 1988-03-22 Eli Lilly And Company Synthetic vaccines for foot and mouth disease
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
EP0273512B1 (en) 1986-12-19 1991-02-27 Duphar International Research B.V Stabilised adjuvant suspension comprising dimethyl dioctadecyl ammonium bromide
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
RU1615918C (ru) * 1989-05-22 1995-07-09 Всероссийский научно-исследовательский институт защиты животных Адъювант
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
US6764682B1 (en) 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
US5824316A (en) 1996-05-24 1998-10-20 The United States Of America As Represented By The Secretary Of Agriculture Leader-proteinase deleted foot-and-mouth disease viruses and their use as vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6214806B1 (en) 1997-02-28 2001-04-10 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
JP2002512619A (ja) 1997-04-30 2002-04-23 メリウクス オラバクス 横隔膜下からの全身経路に使用するための抗ヘリコバクターワクチン組成物、および粘膜／非経口複合免疫法
EP1027033B1 (en) 1997-05-14 2009-07-22 The University Of British Columbia High efficiency encapsulation of nucleic acids in lipid vesicles
EP2085090A3 (en) 1997-06-06 2012-05-02 The Regents of the University of California Inhibitors of DNA immunostimulatory sequence activity
NZ508650A (en) 1998-05-14 2003-05-30 Coley Pharm Gmbh Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
PT1077722E (pt) 1998-05-22 2006-12-29 Coley Pharm Group Inc Produtos e composições para utilização na indução da imunidade mucosal
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
WO2000009159A1 (en) 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
AUPP807399A0 (en) * 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
AU2501700A (en) * 1999-01-12 2000-08-01 Princeton University Glycopeptide antibiotics containing a desmethylvancosamine residue, combinatorial libraries of same and methods of producing same
JP2002537102A (ja) 1999-02-26 2002-11-05 カイロン コーポレイション 吸着された高分子および微粒子を有するミクロエマルジョン
WO2000061184A2 (en) 1999-04-08 2000-10-19 Glenn Gregory M Dry formulation for transcutaneous immunization
US6977245B2 (en) 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
EP1177439B1 (en) 1999-04-29 2004-09-08 Coley Pharmaceutical GmbH Screening for immunostimulatory dna functional modifiers
AU2001227889A1 (en) 2000-01-14 2001-07-24 The United States of America, represented by The Secretary, Department of Health & Human Services Oligodeoxynucleotide and its use to induce an immune response
US20010044416A1 (en) 2000-01-20 2001-11-22 Mccluskie Michael J. Immunostimulatory nucleic acids for inducing a Th2 immune response
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
BR0108566A (pt) 2000-02-21 2002-11-19 Pharmexa As Método para a regulação negativa in vivo de proteìna amilóide em um animal, incluindo um ser humano e para o tratamento e/ou prevenção e/ou melhora da doença de alzheimer ou outras doenças e condições cartacterizadas por depósitos de amilóide, análogo de um polipeptìdeo amiloidogênico,composição imunogênica, fragmento de ácido nucleico, vetor, célula transformada, composição para induzir a produção de anticorpos contra um polipeptìdeo amiloidogênico, linhagem celular estável, métodos para a preparação de uma célula, para a identificação de um polipeptìdeo amiloidogênico modificado, e para preparação de uma composição imunogênica, uso de um polipeptìdeo amiloidogênico ou de uma subsequência do mesmo, e, uso de um análogo de um polipeptìdeo amiloidogênico
US7115579B2 (en) 2000-05-01 2006-10-03 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
GB0025577D0 (en) 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
ATE398175T1 (de) 2000-12-08 2008-07-15 Coley Pharmaceuticals Gmbh Cpg-artige nukleinsäuren und verfahren zu ihrer verwendung
US7244438B2 (en) 2001-01-05 2007-07-17 Intercell Ag Uses for polycationic compounds
US7713942B2 (en) 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
CA2439111A1 (en) 2001-04-05 2002-10-17 Chiron Corporation Mucosal boosting following parenteral priming
US7105495B2 (en) 2001-04-30 2006-09-12 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
EP1390495B1 (en) 2001-05-21 2007-07-04 Intercell AG Immunostimulatory oligodeoxynucleic molecules
AU2002312487A1 (en) 2001-06-15 2003-01-02 Ribapharm Nucleoside vaccine adjuvants
JP2004537543A (ja) 2001-07-02 2004-12-16 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ・ワクチンおよび牛におけるマイコプラズマ・ボビス低減方法
BR0210804A (pt) 2001-07-02 2005-05-03 Pfizer Prod Inc Vacinação de dose única com mycoplásma hyopneumoniae
US7666674B2 (en) 2001-07-27 2010-02-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
WO2003025119A2 (en) 2001-08-03 2003-03-27 Medarex, Inc. Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
CA2456328C (en) 2001-08-07 2015-05-26 Dynavax Technologies Corporation Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
US20030138434A1 (en) 2001-08-13 2003-07-24 Campbell Robert L. Agents for enhancing the immune response
JP4383534B2 (ja) 2001-08-17 2009-12-16 コーリー ファーマシューティカル ゲーエムベーハー 改善した活性を有する組み合わせモチーフ免疫刺激オリゴヌクレオチド
BR0211563A (pt) 2001-08-28 2004-07-13 Pfizer Prod Inc Modelo de infecção por mycoplasma bovis e métodos para administração de m. bovis e para indução de lesões pneumÈnicas do pulmão
ATE447967T1 (de) 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
US20030119774A1 (en) 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
JP2005508945A (ja) 2001-10-06 2005-04-07 メリアル リミテッド Ｃｐｇ配合物及び関連方法
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
RU2212895C2 (ru) 2001-11-01 2003-09-27 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Вакцина против ящура типа о и способ ее изготовления
EP1441763A2 (en) 2001-11-07 2004-08-04 Inex Pharmaceuticals Corp. Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
WO2003047602A1 (en) 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
WO2003066649A1 (en) 2002-02-04 2003-08-14 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
CA2476764A1 (en) 2002-02-19 2003-08-28 Syntherica Corporation Compositions and methods for surrogate antibody modulation of an immune response and transport
AU2003220531B2 (en) * 2002-03-29 2007-11-01 Merck & Co., Inc. Large scale methods of producing adenovirus and adenovirus seed stocks
NZ573064A (en) 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
WO2003089590A2 (en) 2002-04-16 2003-10-30 Vaxin, Inc. TRANSIENT AND/OR PERMANENT MODIFICATION OF SEXUAL BEHAVIOR AND/OR FERTILITY USING RECOMBINANT CHIMERIC GnRH
CN101160399A (zh) 2002-04-22 2008-04-09 拜奥尼茨生命科学公司 寡核苷酸组合物及其在调节免疫应答中的应用
KR100456681B1 (ko) 2002-05-22 2004-11-10 주식회사 대웅 박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
WO2003100040A1 (en) 2002-05-28 2003-12-04 Merck Patent Gmbh A method for generating antigen-presenting cells
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
SE0201701D0 (sv) 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
RU2220744C1 (ru) 2002-07-01 2004-01-10 Федеральное государственное учреждение Всероссийский научно-исследовательский институт защиты животных Вакцина против ящура типа азия-1 и способ ее изготовления
AU2003263963A1 (en) 2002-08-01 2004-02-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
TWI314134B (en) 2002-11-05 2009-09-01 James Hardie Int Finance Bv Calcium silicate hydrate and the method for producing the same
PL378001A1 (pl) 2003-01-29 2006-02-20 Pfizer Products Inc. Szczepionki przeciw Bordetella bronchiseptica dla psów
NZ542323A (en) * 2003-03-26 2008-07-31 Cytos Biotechnology Ag Melan-A peptide analogue-virus-like-particle conjugates
WO2004087204A2 (en) 2003-04-04 2004-10-14 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
ES2409782T3 (es) 2004-04-05 2013-06-27 Zoetis P Llc Emulsiones de aceite en agua microfluidificadas y composiciones de vacuna
WO2006078943A2 (en) * 2005-01-19 2006-07-27 Micro Beef Technologies, Ltd. Method and system for tracking and managing animals and/or food products
AU2006231916A1 (en) 2005-04-07 2006-10-12 Pharmacia & Upjohn Company Llc Formulations and process for production of Bordetella bronchiseptica p68 antigen and vaccines
WO2007053899A1 (en) * 2005-11-10 2007-05-18 Diva Solutions Pty Ltd Differentiating therapeutic composition
PT1991266E (pt) 2006-01-26 2013-08-28 Zoetis P Llc Novas composições adjuvantes glicolipídicas
PT2405002E (pt) * 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleotídeos
US20080038295A1 (en) * 2006-04-13 2008-02-14 Regents Of The University Of Michigan Compositions and methods for orthopox virus vaccination
KR101251707B1 (ko) * 2006-09-27 2013-04-11 콜리 파마슈티칼 게엠베하 면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
US20080292663A1 (en) 2007-05-22 2008-11-27 Gerber Jay D Adjuvant compositions and methods for delivering vaccines
CL2008001806A1 (es) 2007-06-20 2008-09-05 Wyeth Corp Composicion de vacuna en emulsion agua en aceite que comprende un antigeno y un adyuvante en la fase acuosa; y metodo de elaboracion.
PL2310046T3 (pl) * 2008-06-27 2016-09-30 Nowe kompozycje adiuwantowe
PL2402032T3 (pl) 2009-02-27 2020-03-31 Toray Industries, Inc. Kompozycja immunogenna
US20110014232A1 (en) * 2009-07-16 2011-01-20 Agricultural Research Council Chimeric foot and mouth disease viruses
SI2475384T1 (sl) * 2009-09-10 2016-12-30 Merial, Inc. Nove formulacije cepiva, ki obsegajo adjuvante, vsebujoče saponin
WO2011091027A2 (en) 2010-01-19 2011-07-28 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant live attenuated foot-and-mouth disease (fmd) vaccine containing mutations in the l protein coding region
JP2011251963A (ja) * 2010-05-28 2011-12-15 Coley Pharmaceutical Group Inc 抗原および免疫調節ワクチンおよびコレステロール、ならびにその使用
US8765141B2 (en) 2010-07-01 2014-07-01 The United States Of America, As Represented By The Secretary Of Agriculture Development of a marker foot and mouth disease virus vaccine candidate that is attenuated in the natural host
JP5833145B2 (ja) 2011-02-04 2015-12-16 ゾエティス・エルエルシー 免疫原性ｂｏｒｄｅｔｅｌｌａｂｒｏｎｃｈｉｓｅｐｔｉｃａ組成物
EP2919808B1 (en) 2012-11-16 2020-07-29 United Biomedical, Inc. Synthetic peptide-based emergency vaccine against foot and mouth disease (fmd)
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
JP6586083B2 (ja) 2013-09-19 2019-10-02 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
SI3244920T1 (sl) * 2015-01-16 2023-09-29 The United States of America, represented by The Secretary of Agriculture, United States Department of Agriculture Cepivo proti slinavki in parkljevki
US10035841B2 (en) 2016-01-29 2018-07-31 The Texas A&M University System Monoclonal antibody against novel epitopes of foot-and-mouth disease virus protein 3ABC and uses thereof
US10172933B2 (en) 2016-10-31 2019-01-08 The United States Of America, As Represented By The Secretary Of Agriculture Mosaic vaccines for serotype a foot-and-mouth disease virus

Also Published As

Publication number Publication date
HK1246659A1 (zh) 2018-09-14
JP7232225B2 (ja) 2023-03-02
CN115317600A (zh) 2022-11-11
KR102382773B1 (ko) 2022-04-04
JP2022130383A (ja) 2022-09-06
RU2698305C2 (ru) 2019-08-26
PH12017501257A1 (en) 2017-10-30
CN114699518A (zh) 2022-07-05
HUE063288T2 (hu) 2024-01-28
CN114699518B (zh) 2024-07-02
US20200078456A1 (en) 2020-03-12
CN107106674A (zh) 2017-08-29
US11865171B2 (en) 2024-01-09
EP3244920A1 (en) 2017-11-22
AU2016206525A1 (en) 2017-07-13
MX2021015972A (es) 2022-02-10
JP7361867B2 (ja) 2023-10-16
CO2017007057A2 (es) 2017-10-31
SI3244920T1 (sl) 2023-09-29
US20220088173A1 (en) 2022-03-24
EP4248992A3 (en) 2023-12-27
US10478487B2 (en) 2019-11-19
US10967058B2 (en) 2021-04-06
ES2950822T3 (es) 2023-10-13
DK3244920T5 (da) 2024-10-07
EP4248992A2 (en) 2023-09-27
JP7506708B2 (ja) 2024-06-26
KR102508719B1 (ko) 2023-03-09
ZA201704596B (en) 2018-05-30
LT3244920T (lt) 2023-08-25
US20240197855A1 (en) 2024-06-20
FI3244920T3 (fi) 2023-08-04
US20180264101A1 (en) 2018-09-20
SG11201705737RA (en) 2017-08-30
KR20220044395A (ko) 2022-04-07
JP7113620B2 (ja) 2022-08-05
KR20200068759A (ko) 2020-06-15
DK3244920T3 (da) 2023-06-26
WO2016115456A1 (en) 2016-07-21
IL253137A0 (en) 2017-08-31
JP2021001205A (ja) 2021-01-07
CA2973828C (en) 2023-09-19
KR20170097116A (ko) 2017-08-25
AU2021257973A1 (en) 2021-11-25
AR103427A1 (es) 2017-05-10
PT3244920T (pt) 2023-07-28
IL253137B2 (en) 2024-03-01
MX2017009306A (es) 2017-11-08
RU2017124186A (ru) 2019-02-18
RU2017124186A3 (hr) 2019-02-18
CA2973828A1 (en) 2016-07-21
BR112017015288A2 (pt) 2018-01-16
JP2018502166A (ja) 2018-01-25
EP3244920B1 (en) 2023-06-07
PL3244920T3 (pl) 2023-09-25
JP2023012507A (ja) 2023-01-25
IL253137B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
HRP20230752T1 (hr) Cjepivo protiv slinavke i šapa
CY1124618T1 (el) Ανασυνδυασμενοι hvt φορεις οι οποιοι εκφραζουν αντιγονα παθογονων των πτηνων και χρησεις αυτων
JP2017530124A5 (hr)
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
CO2019011548A2 (es) Vacunas contra el gallid herpesvirus 3 recombinante que codifican antígenos patogénicos aviares heterólogos
MX2019007349A (es) Vacuna combinada para cerdos.
JOP20190088A1 (ar) نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
CL2017003224A1 (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante
PH12017500216A1 (en) Vaccine in serotype-9 fowl adenovirus recombinant vector
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
JP2016508999A5 (hr)
MX2023007395A (es) Vacunas del virus de la peste porcina africana (ppa).
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
MX2018001815A (es) Vacunas de herpesvirus de pavo recombiante y uso de las mismas.
PH12018501368A1 (en) M hyo multivalent vaccine and uses thereof
PH12018502436A1 (en) Multivalent vaccines major swine viral diseases
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
EA202191145A1 (ru) Вакцина виб 4/91 с гетерологичным шиповидным белком
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
WO2020012428A8 (en) New vaccines against avian reoviruses
AR115002A1 (es) Ehv con ul18 y/o ul8 inactivados
MX2022007217A (es) Vacuna epitópica para virus de fiebre porcina africana.
BR112022007474A2 (pt) Vacina de partículas semelhantes a vírus chikungunya e métodos de uso da mesma
GT201400199A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él